We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever

By LabMedica International staff writers
Posted on 15 Jun 2026

Louse-borne relapsing fever is a neglected infection caused by Borrelia recurrentis and spread by body lice, with untreated mortality reaching up to 20%. More...

Recurrent febrile episodes complicate recognition and triage, and sporadic outbreaks persist in parts of the Horn of Africa. How the pathogen persists in the human host has been unclear, hindering targeted diagnostics. Researchers have now identified outer surface proteins that drive immune evasion and form the basis for new serological tests.

At Goethe University Frankfurt and Universitätsmedizin Frankfurt, investigators identified and characterized five closely related outer surface proteins in B. recurrentis, termed Chi proteins, that are critical for survival in humans. Working with Justus Liebig University Giessen, the team showed the proteins share a common ancestry and functional profile. The work delineates how the organism withstands first-line host defenses during bloodstream infection.

The Chi proteins bind specific blood proteins to suppress activation of the human complement system, a central arm of innate immunity that tags and eliminates bacteria. By blocking complement-mediated opsonization, they prevent immune recognition and clearance. The proteins also capture plasminogen and convert it into active plasmin, facilitating tissue invasion after entry into the host.

The findings were published in Nature Communications. Louse-borne relapsing fever, transmitted by body lice, is classified as a poverty-related neglected disease and can be fatal in up to 20% of untreated cases. Sporadic outbreaks are reported in countries around the Horn of Africa, and rising case detection among refugees drew attention in Europe in 2015, although individual studies indicate European body lice currently do not carry the pathogen.

Building on these results, the researchers have developed diagnostic tests and are conducting serological studies in Kenya and Nigeria. The proteins may also represent candidates for vaccine development. Targeted assays for fever of unknown origin could enable timely, pathogen-specific antibiotic therapy, and preparedness remains important despite the current absence of infected body lice in Europe.

"We know from other pathogens that they use the body's own plasmin to invade tissues. Together with the ability of the Chi proteins to block the complement system, this gives Borrelia recurrentis significant advantages in surviving and spreading after entering the human body," said Peter Kraiczy, head of the Borrelia research group at the Institute of Medical Microbiology and Infection Control at Universitätsmedizin Frankfurt and Goethe University.

"Fever of unknown origin occurs in many infectious diseases, so pathogen-specific tests make it possible to quickly initiate the appropriate antibiotic treatment against the causative agent. We have already made considerable progress in this area and are currently conducting studies in Kenya and Nigeria using serological tests developed in our laboratory," added Peter Kraiczy.

Related Links
Goethe University Frankfurt 
Universitätsmedizin Frankfurt
Justus Liebig University Giessen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.